JFB upholds rigorous editorial policies to protect research integrity and ensure reliable fertility biomarker scholarship. All submissions are evaluated for scope fit, ethical compliance, and reporting quality.

• Compliance with COPE and institutional ethics standards
• Informed consent and patient privacy protections
• Disclosure of conflicts of interest and funding sources
• Adherence to applicable regulatory requirements

JFB uses a single blind peer review model. Reviewers evaluate methodological rigor, diagnostic clarity, and clinical relevance.

• Confidential reviewer identities
• Structured editorial oversight
• Clear revision guidance

• STROBE for observational studies
• CONSORT for randomized trials
• PRISMA for systematic reviews
• CARE for case reports
• TREND for non randomized evaluations

• Data availability statements required
• Disclosure of analytic code or models when feasible
• Clear description of diagnostic criteria and staging
• Declaration of deviations from protocols
• Confirm compliance with COPE guidelines and ethical review standards.
• Disclose conflicts of interest and funding transparency requirements.
• State data sharing expectations and patient consent obligations.
• Outline authorship criteria and contributor role documentation.
• Specify plagiarism screening and similarity check procedures.
• Describe corrections, retractions, and expression of concern workflows.
• Clarify preprint and prior publication policies.
• Document peer review model and reviewer confidentiality expectations.
• Provide guidance on clinical trial registration requirements.
• Describe image integrity checks and manipulation policies.
• Specify requirements for data availability statements.
• Clarify policies on AI assisted writing or analysis disclosures.
• Outline appeal processes for editorial decisions.
• State expectations for reporting adverse events and safety data.
• Describe policies for patient privacy and deidentification.
• Provide guidance on protocol deviations and amendments.
• Describe policy for data fabrication or falsification investigations.
• Clarify policy on dual submission to other journals.
• Describe procedures for handling whistleblower reports.
• Outline responsibilities for corresponding author verification.
• Define policy on image duplication or manipulation screening.
• State expectations for clinical trial registry updates after publication.
• Describe policy on reporting adverse events and safety monitoring.
• Clarify requirements for reporting guideline adherence.
• Outline expectations for imaging and pathology data transparency.
• Specify policy for handling patient consent withdrawals.
• Describe procedures for corrections to staging or outcome data.
• Clarify requirements for reporting staging systems used.
• Describe expectations for reporting molecular testing methods.
• Specify policy for data sharing in clinical trials.

Suspected misconduct, plagiarism, or data fabrication is investigated according to COPE guidance. Corrections, retractions, or expressions of concern are issued when necessary.

Authors may appeal decisions with a written rationale. Appeals are reviewed by senior editors. Questions or complaints can be directed to [email protected].

JFB is committed to rigorous, transparent publishing in fertility biomarker research and reproductive medicine. We emphasize reproducible laboratory methods, clear reporting of diagnostic criteria, and ethical compliance across all article types.

The editorial office supports authors, editors, and reviewers with clear guidance and responsive communication. For questions about scope or workflow, contact [email protected].

We encourage continuous improvement in reporting practices and share updates that help the community maintain high standards in biomarker validation, reproductive outcomes, and translational fertility science.